RS50381B - Policikloalkilpurini kao adenozin receptor antagonisti - Google Patents

Policikloalkilpurini kao adenozin receptor antagonisti

Info

Publication number: RS50381B
Authority: RS; Serbia
Prior art keywords: polycycloalkylpurines; receptor antagonists; adenosine receptor; adenosine; disorders
Prior art date: 1999-11-12

Application number

YUP-338/02A

Other languages

English (en)

Inventor

William F. Kiesman

James E. Dowling

He Xi Chang

Carol L. Ensinger

Gnanasambandam Kumaravel

Ko Chung Lin

Russell C. Petter

Original Assignee

Biogen Idec Ma Inc.,

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-11-12

Filing date

2000-11-13

Publication date

2009-11-10

2000-11-13 Application filed by Biogen Idec Ma Inc., filed Critical Biogen Idec Ma Inc.,

2006-01-16 Publication of YU33802A publication Critical patent/YU33802A/sh

2009-11-10 Publication of RS50381B publication Critical patent/RS50381B/sr

Links

229940121359 adenosine receptor antagonist Drugs 0.000 title 1
239000000296 purinergic P1 receptor antagonist Substances 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
150000001875 compounds Chemical class 0.000 abstract 2
201000010099 disease Diseases 0.000 abstract 2
108010060263 Adenosine A1 Receptor Proteins 0.000 abstract 1
102000030814 Adenosine A1 receptor Human genes 0.000 abstract 1
229940124639 Selective inhibitor Drugs 0.000 abstract 1
239000002598 adenosine A1 receptor antagonist Substances 0.000 abstract 1
230000000747 cardiac effect Effects 0.000 abstract 1
210000003169 central nervous system Anatomy 0.000 abstract 1
230000003412 degenerative effect Effects 0.000 abstract 1
239000002934 diuretic Substances 0.000 abstract 1
230000001882 diuretic effect Effects 0.000 abstract 1
230000003389 potentiating effect Effects 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
208000023504 respiratory system disease Diseases 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/22—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one sulfur atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Cardiology (AREA)
Biomedical Technology (AREA)
Heart & Thoracic Surgery (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Hematology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Hospice & Palliative Care (AREA)
Obesity (AREA)
Urology & Nephrology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Psychology (AREA)
Gastroenterology & Hepatology (AREA)
Vascular Medicine (AREA)
Dermatology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

YUP-338/02A 1999-11-12 2000-11-13 Policikloalkilpurini kao adenozin receptor antagonisti RS50381B (sr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US16519199P	1999-11-12	1999-11-12

Publications (2)

Publication Number	Publication Date
YU33802A YU33802A (sh)	2006-01-16
RS50381B true RS50381B (sr)	2009-11-10

Family

ID=22597852

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
YUP-338/02A RS50381B (sr)	1999-11-12	2000-11-13	Policikloalkilpurini kao adenozin receptor antagonisti

Country Status (35)

Country	Link
US (5)	US6649600B1 (sr)
EP (3)	EP2070930A1 (sr)
JP (1)	JP2003513982A (sr)
KR (2)	KR100863761B1 (sr)
CN (2)	CN100390178C (sr)
AT (1)	ATE424403T1 (sr)
AU (1)	AU784556B2 (sr)
BG (1)	BG65720B1 (sr)
BR (1)	BR0015545A (sr)
CA (1)	CA2390496A1 (sr)
CY (1)	CY1110512T1 (sr)
CZ (1)	CZ20021614A3 (sr)
DE (1)	DE60041710D1 (sr)
DK (1)	DK1230243T3 (sr)
EA (1)	EA005211B1 (sr)
EE (1)	EE05365B1 (sr)
ES (1)	ES2323357T3 (sr)
GE (1)	GEP20043303B (sr)
HK (1)	HK1049155B (sr)
IL (1)	IL149487A0 (sr)
IS (1)	IS6379A (sr)
ME (1)	MEP42208A (sr)
MX (1)	MXPA02004796A (sr)
NO (1)	NO328956B1 (sr)
NZ (2)	NZ519426A (sr)
PL (1)	PL206890B1 (sr)
PT (1)	PT1230243E (sr)
RS (1)	RS50381B (sr)
SI (1)	SI1230243T1 (sr)
SK (1)	SK287311B6 (sr)
TR (1)	TR200201260T2 (sr)
TW (1)	TWI272270B (sr)
UA (1)	UA77391C2 (sr)
WO (1)	WO2001034610A1 (sr)
ZA (1)	ZA200203701B (sr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2070930A1 (en) *	1999-11-12	2009-06-17	Biogen Idec MA, Inc.	Polycycloalkylpurines as adenosine receptor antagonists
EP1775297A3 (en) *	1999-11-12	2008-12-03	Biogen Idec MA Inc.	Adenosine receptor antagonists and methods of making and using the same
UA80258C2 (en) *	2001-09-06	2007-09-10	Biogen Inc	Methods of treating pulmonary disease
DE10145193C1 (de)	2001-09-13	2003-03-13	Sachtler Gmbh & Co Kg	Körpermontierbares Kameratragesystem mit einem multifunktionalen Verbund elektrischer Komponenten
CN1671716A (zh) *	2002-06-12	2005-09-21	拜奥根Idec马萨诸塞公司	用腺苷受体拮抗剂治疗缺血再灌注损伤的方法
EP1521584A1 (en)	2002-06-17	2005-04-13	Glaxo Group Limited	Purine derivatives as liver x receptor agonists
WO2004009594A2 (en) *	2002-07-19	2004-01-29	Aryx Therapeutics	Xanthine derivatives having adenosine a1-receptor antagonist properties
US7202252B2 (en)	2003-02-19	2007-04-10	Endacea, Inc.	A1 adenosine receptor antagonists
US20040229901A1 (en) *	2003-02-24	2004-11-18	Lauren Otsuki	Method of treatment of disease using an adenosine A1 receptor antagonist
CA2522971A1 (en) *	2003-04-25	2004-11-11	Novacardia, Inc.	Method of improved diuresis in individuals with impaired renal function
CA2528385C (en)	2003-06-06	2011-03-15	Endacea, Inc.	A1 adenosine receptor antogonists
MX2007015863A (es) *	2005-06-17	2008-04-02	Apogee Biotechnology Corp	Inhibidores de esfingosina cinasa.
WO2007059330A2 (en) *	2005-11-17	2007-05-24	Medkura Inc.	Cubane nucleoside analogs
WO2007117549A2 (en) *	2006-04-06	2007-10-18	Novacardia, Inc.	Co-administration of adenosine a1 receptor antagonists and anticonvulsants
CN101085785B (zh) *	2006-06-06	2011-09-21	中国科学院上海药物研究所	用于治疗乙型肝炎的嘌呤类化合物及其制备方法和用途，以及包括该化合物的组合物
CN101466383A (zh) *	2006-06-16	2009-06-24	美国诺华卡迪亚公司	包含低频率投与aa1ra的肾功能延长改善
BRPI0714350B1 (pt) *	2006-07-17	2017-03-07	Tyratech Inc	composições e métodos para controle de insentos
US20090197900A1 (en) *	2007-03-29	2009-08-06	Howard Dittrich	Methods of treating heart failure and renal dysfunction in individuals with an adenosine a1 receptor antagonist
WO2008121882A1 (en) *	2007-03-29	2008-10-09	Novacardia, Inc.	Improved methods of administration of adenosine a1 receptor antagonists
EP2222676A4 (en) *	2007-12-21	2011-10-26	Endacea Inc	A1-adenosine receptor antagonistic
WO2009152458A1 (en) *	2008-06-13	2009-12-17	Biogen Idec Ma Inc.	Liquid formulation suitable for infusion comprising an adenosine receptor antagonist for treating heart failure and renal insufficiency.
WO2010011917A1 (en) *	2008-07-25	2010-01-28	Glaxosmithkline Llc	SEH AND 11β-HSD1 DUAL INHIBITORS
WO2011063268A2 (en)	2009-11-19	2011-05-26	Biogen Idec Ma Inc	Novel synthetic methods
AU2010327316B2 (en) *	2009-12-04	2014-10-16	Commonwealth Scientific And Industrial Research Organisation	Polymeric materials
CN101709034B (zh) *	2009-12-14	2017-05-31	大连九信精细化工有限公司	双环[2.2.2]辛烷‑1，4‑二羧酸单甲酯的合成方法
AR084457A1 (es) *	2010-12-22	2013-05-15	Lundbeck & Co As H	Derivados de biciclo[3,2,1]octilamida
AU2012275499A1 (en)	2011-06-27	2013-12-19	Kyorin Pharmaceutical Co., Ltd.	Bridged bicyclic compounds for the treatment of bacterial infections
US8962660B2 (en)	2013-03-14	2015-02-24	Bristol-Myers Squibb Company	Oxabicyclo [2.2.2] acid GPR120 modulators
AU2014244482B2 (en) *	2013-03-14	2018-01-25	Bristol-Myers Squibb Company	Bicyclo [2.2.2] acid GPR120 modulators
LT6401B (lt)	2015-07-28	2017-06-12	Vilniaus Universitetas	Karboanhidrazės selektyvūs inhibitoriai
CN109843846B (zh)	2016-10-19	2022-07-05	伊士曼化工公司	双环[2.2.2]辛烷的合成
US11548893B2 (en)	2017-07-15	2023-01-10	Arisan Therapeutics Inc.	Enantiomerically pure adamantane carboxamides for the treatment of filovirus infection
KR102616949B1 (ko)	2017-09-14	2023-12-22	다이이찌 산쿄 가부시키가이샤	고리형 구조를 갖는 화합물
CN111433181B (zh)	2017-10-11	2023-08-04	伊士曼化工公司	双环[2.2.2]辛烷衍生物的合成
JP7212693B2 (ja)	2017-11-01	2023-01-25	ブリストル－マイヤーズスクイブカンパニー	ファルネソイドｘ受容体モジュレーターとしての架橋二環化合物
ES2941774T3 (es)	2018-09-18	2023-05-25	Bristol Myers Squibb Co	Acidos oxabiciclo como antagonistas de LPA
US10836899B2 (en)	2018-12-13	2020-11-17	Eastman Chemical Company	Polyesters with specified crystallization half-times

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0011399A1 (en)	1978-11-11	1980-05-28	FISONS plc	N-substituted theophyllines, processes for their preparation and pharmaceutical compositions containing them
DE3843117A1 (de) *	1988-12-22	1990-06-28	Boehringer Ingelheim Kg	Neue xanthinderivate mit adenosin-antagonistischer wirkung
US5290782A (en) *	1989-09-01	1994-03-01	Kyowa Hakko Kogyo Co., Ltd.	Xanthine derivatives
JPH06102662B2 (ja) *	1989-09-01	1994-12-14	協和醗酵工業株式会社	キサンチン誘導体
CA2028235C (en)	1989-10-20	1997-01-21	Fumio Suzuki	Condensed purine derivatives
DE4019892A1 (de) *	1990-06-22	1992-01-02	Boehringer Ingelheim Kg	Neue xanthinderivate
JPH04270222A (ja) *	1991-02-25	1992-09-25	Kyowa Hakko Kogyo Co Ltd	脳機能改善剤
JPH0559056A (ja) *	1991-02-25	1993-03-09	Kyowa Hakko Kogyo Co Ltd	キサンチン誘導体
CA2061544A1 (en) *	1991-02-25	1992-08-26	Fumio Suzuki	Xanthine compounds
JPH04346986A (ja) *	1991-05-23	1992-12-02	Kyowa Hakko Kogyo Co Ltd	トリチウム標識化されたキサンチン誘導体
JP3115128B2 (ja) *	1991-11-08	2000-12-04	協和醗酵工業株式会社	キサンチン誘導体
CA2082325A1 (en)	1991-11-08	1993-05-09	Fumio Suzuki	Xanthine derivatives
US5336769A (en) *	1992-02-17	1994-08-09	Kyowa Hakko Kogyo Co., Ltd.	Xanthine derivatives
JPH0616668A (ja) *	1992-03-12	1994-01-25	Kyowa Hakko Kogyo Co Ltd	キサンチン誘導体
US5342841A (en)	1992-03-12	1994-08-30	Kyowa Hakko Kogyo Co., Ltd.	Xanthine derivatives
TW252044B (sr) *	1992-08-10	1995-07-21	Boehringer Ingelheim Kg
US5384176A (en) *	1992-12-11	1995-01-24	Zimmerman; Richard C.	Phenolic acid sulfate esters for prevention of marine biofouling
WO1994016702A1 (en) *	1993-01-26	1994-08-04	Kyowa Hakko Kogyo Co., Ltd.	Remedy for irregular bowel movement
US5395836A (en) *	1993-04-07	1995-03-07	Kyowa Hakko Kogyo Co., Ltd.	8-tricycloalkyl xanthine derivatives
JP3729874B2 (ja) *	1993-04-07	2005-12-21	協和醗酵工業株式会社	キサンチン誘導体
US5446046A (en) *	1993-10-28	1995-08-29	University Of Florida Research Foundation	A1 adenosine receptor agonists and antagonists as diuretics
WO1998057644A1 (fr) *	1997-06-16	1998-12-23	Kyowa Hakko Kogyo Co., Ltd.	Agent de prevention et remede contre la nephropathie induite par les medicaments
WO1998057645A1 (fr) *	1997-06-16	1998-12-23	Kyowa Hakko Kogyo Co., Ltd.	Medicament contre l'oedeme hepatique
DE19816857A1 (de) *	1998-04-16	1999-10-21	Boehringer Ingelheim Pharma	Neue unsymmetrisch substituierte Xanthin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CA2295101C (en)	1998-04-24	2009-06-30	Biogen, Inc.	Adenosine a1 receptor antagonist containing composition and method for restoring diuretic and renal function
EP0955301A3 (en) *	1998-04-27	2001-04-18	Pfizer Products Inc.	7-aza-bicyclo[2.2.1]-heptane derivatives, their preparation and use according to their affinity for neuronal nicotinic acetylcholine receptors
ES2284256T3 (es)	1998-07-02	2007-11-01	Kyowa Hakko Kogyo Co., Ltd.	Medicamentos para la diabetes.
EP1775297A3 (en) *	1999-11-12	2008-12-03	Biogen Idec MA Inc.	Adenosine receptor antagonists and methods of making and using the same
EP2070930A1 (en) *	1999-11-12	2009-06-17	Biogen Idec MA, Inc.	Polycycloalkylpurines as adenosine receptor antagonists
DE60304911D1 (de)	2002-02-25	2006-06-08	Eisai Co Ltd	Xanthin-Derivate als DPP-IV-Inhibitoren
WO2004009594A2 (en) *	2002-07-19	2004-01-29	Aryx Therapeutics	Xanthine derivatives having adenosine a1-receptor antagonist properties
US7129239B2 (en)	2002-10-28	2006-10-31	Pfizer Inc.	Purine compounds and uses thereof
EP1781657B1 (en) *	2004-02-14	2013-03-27	GlaxoSmithKline Intellectual Property Development Limited	Medicaments with hm74a receptor activity

2000
- 2000-11-13 EP EP09151275A patent/EP2070930A1/en not_active Withdrawn
- 2000-11-13 CA CA002390496A patent/CA2390496A1/en not_active Abandoned
- 2000-11-13 KR KR1020027006093A patent/KR100863761B1/ko not_active IP Right Cessation
- 2000-11-13 US US09/711,543 patent/US6649600B1/en not_active Expired - Fee Related
- 2000-11-13 MX MXPA02004796A patent/MXPA02004796A/es active IP Right Grant
- 2000-11-13 DK DK00978546T patent/DK1230243T3/da active
- 2000-11-13 AU AU16000/01A patent/AU784556B2/en not_active Ceased
- 2000-11-13 RS YUP-338/02A patent/RS50381B/sr unknown
- 2000-11-13 NZ NZ519426A patent/NZ519426A/en not_active IP Right Cessation
- 2000-11-13 GE GE4819A patent/GEP20043303B/en unknown
- 2000-11-13 EP EP00978546A patent/EP1230243B1/en not_active Expired - Lifetime
- 2000-11-13 CZ CZ20021614A patent/CZ20021614A3/cs unknown
- 2000-11-13 AT AT00978546T patent/ATE424403T1/de active
- 2000-11-13 SI SI200031029T patent/SI1230243T1/sl unknown
- 2000-11-13 EE EEP200200247A patent/EE05365B1/xx not_active IP Right Cessation
- 2000-11-13 DE DE60041710T patent/DE60041710D1/de not_active Expired - Lifetime
- 2000-11-13 ES ES00978546T patent/ES2323357T3/es not_active Expired - Lifetime
- 2000-11-13 CN CNB008164398A patent/CN100390178C/zh not_active Expired - Fee Related
- 2000-11-13 ME MEP-422/08A patent/MEP42208A/xx unknown
- 2000-11-13 PL PL356033A patent/PL206890B1/pl not_active IP Right Cessation
- 2000-11-13 SK SK663-2002A patent/SK287311B6/sk not_active IP Right Cessation
- 2000-11-13 WO PCT/US2000/031058 patent/WO2001034610A1/en active IP Right Grant
- 2000-11-13 EA EA200200560A patent/EA005211B1/ru not_active IP Right Cessation
- 2000-11-13 CN CNA2008100921415A patent/CN101255162A/zh active Pending
- 2000-11-13 UA UA2002064822A patent/UA77391C2/uk unknown
- 2000-11-13 BR BR0015545-4A patent/BR0015545A/pt not_active Application Discontinuation
- 2000-11-13 TR TR2002/01260T patent/TR200201260T2/xx unknown
- 2000-11-13 JP JP2001537323A patent/JP2003513982A/ja active Pending
- 2000-11-13 PT PT00978546T patent/PT1230243E/pt unknown
- 2000-11-13 IL IL14948700A patent/IL149487A0/xx not_active IP Right Cessation
- 2000-11-13 NZ NZ527917A patent/NZ527917A/en not_active IP Right Cessation
- 2000-11-13 KR KR1020087005528A patent/KR20080027971A/ko not_active Application Discontinuation
- 2000-11-13 EP EP10183076A patent/EP2305684A1/en not_active Withdrawn
- 2000-12-15 TW TW089123845A patent/TWI272270B/zh active
2002
- 2002-05-09 ZA ZA200203701A patent/ZA200203701B/xx unknown
- 2002-05-10 IS IS6379A patent/IS6379A/is unknown
- 2002-05-10 NO NO20022238A patent/NO328956B1/no not_active IP Right Cessation
- 2002-05-31 BG BG106762A patent/BG65720B1/bg unknown
- 2002-12-23 HK HK02109310.2A patent/HK1049155B/zh not_active IP Right Cessation
2003
- 2003-08-21 US US10/646,454 patent/US20040067966A1/en not_active Abandoned
2006
- 2006-07-10 US US11/484,805 patent/US7579354B2/en not_active Expired - Fee Related
- 2006-07-13 US US11/487,764 patent/US20070015732A1/en not_active Abandoned
2009
- 2009-02-10 US US12/368,469 patent/US20090221821A1/en not_active Abandoned
- 2009-05-21 CY CY20091100543T patent/CY1110512T1/el unknown

Also Published As

Publication number	Publication date
SK6632002A3 (en)	2003-02-04
CN101255162A (zh)	2008-09-03
NZ527917A (en)	2005-03-24
NO20022238D0 (no)	2002-05-10
US6649600B1 (en)	2003-11-18
CN1402729A (zh)	2003-03-12
US7579354B2 (en)	2009-08-25
NO20022238L (no)	2002-07-12
KR20020049050A (ko)	2002-06-24
IS6379A (is)	2002-05-10
TR200201260T2 (tr)	2002-09-23
ES2323357T3 (es)	2009-07-14
CA2390496A1 (en)	2001-05-17
PL206890B1 (pl)	2010-10-29
MEP42208A (en)	2011-02-10
EE05365B1 (et)	2010-12-15
US20060252730A1 (en)	2006-11-09
EP2305684A1 (en)	2011-04-06
MXPA02004796A (es)	2007-01-30
WO2001034610A1 (en)	2001-05-17
HK1049155B (zh)	2009-11-06
KR20080027971A (ko)	2008-03-28
PL356033A1 (en)	2004-06-14
SI1230243T1 (sl)	2009-08-31
EP1230243A1 (en)	2002-08-14
DK1230243T3 (da)	2009-06-15
EA005211B1 (ru)	2004-12-30
NO328956B1 (no)	2010-06-28
BG65720B1 (bg)	2009-08-31
DE60041710D1 (de)	2009-04-16
BR0015545A (pt)	2002-08-06
CZ20021614A3 (cs)	2002-07-17
AU784556B2 (en)	2006-05-04
US20070015732A1 (en)	2007-01-18
EE200200247A (et)	2003-06-16
UA77391C2 (en)	2006-12-15
TWI272270B (en)	2007-02-01
HK1049155A1 (en)	2003-05-02
PT1230243E (pt)	2009-06-12
AU1600001A (en)	2001-06-06
GEP20043303B (en)	2004-01-12
YU33802A (sh)	2006-01-16
KR100863761B1 (ko)	2008-10-16
ATE424403T1 (de)	2009-03-15
EP2070930A1 (en)	2009-06-17
EP1230243B1 (en)	2009-03-04
CN100390178C (zh)	2008-05-28
ZA200203701B (en)	2004-02-23
CY1110512T1 (el)	2015-04-29
EA200200560A1 (ru)	2002-10-31
IL149487A0 (en)	2002-11-10
US20040067966A1 (en)	2004-04-08
JP2003513982A (ja)	2003-04-15
SK287311B6 (sk)	2010-06-07
BG106762A (en)	2003-01-31
NZ519426A (en)	2003-08-29
US20090221821A1 (en)	2009-09-03

Publication	Publication Date	Title
HK1049155A1 (en)	2003-05-02	Polycycloalkylpurines as adenosine receptor antagonists
HK1049153A1 (en)	2003-05-02	Adenosine receptor antagonists and methods of making and using the same
HK1085724A1 (en)	2006-09-01	3,6-disubstituted azabicyclo 3.1.0-hexane derivatives as muscarinic receptor antagonists
IL147977A0 (en)	2002-09-12	Substituted 1,5-dihydropyrrol-2-on derivatives as nmda receptor antagonists for the treatment of pain
CA2094702A1 (en)	1992-05-06	Substituted tetrahydropyridines and hydroxypiperidines as central nervous system agents
GB9815618D0 (en)	1998-09-16	Treatment of dyskinesia
ATE256126T1 (de)	2003-12-15	5-heteroatom-alkyl substituierte 3-oxo-pyrido(1,2-a)benzimidazol-4-carboxamid derivate zur behandlung zentral nervöser system störungen
SI1200402T1 (sl)	2006-02-28	Substituirani 1,5-dihidropirol-2-on-derivati, ucinkoviti kot antagonisti NMDA-receptorja za tretiranje bolecinskih stanj